Acrivon Therapeutics To Highlight AP3 Platform For Pathway-Based Drug Discovery And Development At AACR D3 July 21-24
Acrivon Therapeutics Inc ACRV
$1.50
▼ -1.32%
($-0.02)
🗓️ Earnings Next Week
Open
$1.57
Prev Close
$1.52
Day Range
$1.50 – $1.64
52W Range
$1.20 – $3.56
Market Cap
$64.20M
Beta
1.89
EPS (TTM)
$-2.00
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2022-11-15 |
| Shares Out. | 42,800,000 |
| Website | acrivon.com/ ↗ |
| Phone | 16172078979 |
| Employees | 76 |
| Net Income | -$19.0M |
| Free Cash Flow | -$66.3M |
| Total Assets | $107.8M |
| Total Liabilities | $12.3M |
| Equity | $95.5M |
About Acrivon Therapeutics Inc
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
Acrivon Therapeutics Inc is a publicly traded company under the ticker symbol ACRV on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-07-01)